VEGFA and neoplasm: Combining immunotherapy strategies and blockade of the VEGF axis seems promising, changes tumor vasculature and immune responses in melanoma (Hodi et al., 2014) and has improved outcomes of NSCLC patients in clinical studies (Socinski et al., 2018).